One of the benefits to raking in $6.7 billion in free cash flow is that you can splurge a little if you don't feel like developing something in-house.
Such is the case with Merck
The drugmaker is paying $130 million for Insmed's
Merck and Eli Lilly
The purchase by Merck helps it catch up a little, and it should put the company in a good position to be able to submit a marketing application in the U.S., once the FDA starts accepting them. When it comes to revenue growth, Merck can certainly use all the help it can get.